Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT06526182Phase 3Active, not recruiting
- Sponsor
- Almirall
- Start
- Jul 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Started Jul 2024; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06526182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526182.